trial

PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia

NCTId NCT05462340
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 117 (actual)
Sponsored by Washington University School of Medicine
Primary completion 2025-01-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
117 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2022-08-18
Primary completion
2025-01-07
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
[18F]ASEM[18F]AZAN

Sponsors

Washington University School of MedicineLead Sponsor

Sites

1 total
St Louis, United States

Facts & assertions

4 sourced
Enrollment
117
Phase
PHASE1
Primary Completion Date
2025-01-07
Status
TERMINATED
relationships
The graph out of here
drug
[18F]ASEM
drug
[18F]AZAN
drug
lead_sponsor
Washington University School of Medicine
company
indication
Schizophrenia
indication
Schizophrenia
indication